Dendritic cells transfected with adenoviral vectors as vaccines

Methods in Molecular Biology

Volumn 1139, Issue , 2014, Pages 97-118

  Senesac, Joseph ^a   Gabrilovich, Dmitry ^b   Pirruccello, Samuel ^c   Talmadge, James E ^c  

^a Bellicum Pharmaceuticals   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Dendritic cells; Monocytes; Release assays; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; DENDRITIC CELL VACCINE; GUANOSINE PHOSPHATE; CANCER VACCINE;

APHERESIS; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; GOOD MANUFACTURING PRACTICE; MONOCYTE; PHENOTYPE; TRANSGENE; VIRAL GENE THERAPY; ADENOVIRUS; CELL ADHESION; CELL SEPARATION; CRYOPRESERVATION; CULTURE TECHNIQUE; CYTOLOGY; DENDRITIC CELL; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY;

ADENOVIRIDAE;

ADENOVIRIDAE; BLOOD COMPONENT REMOVAL; CANCER VACCINES; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL SEPARATION; CRYOPRESERVATION; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; MONOCYTES; PHENOTYPE; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84909620016     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0345-0_10     Document Type: Article

References (30)

1. Kantoff PW et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
2. Sakurai F (2003) Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 8:813-821
3. Morse MA et al (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56-58
4. Reichardt VL et al (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 93:2411-2419
5. Gallo P et al (2005) Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 12(Supplement 1):S84-S91
6. Schoggins JW, Falck-Pedersen E (2006) Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity. J Virol 80:10634-10644
7. Rouard H et al (2000) Adenoviral transduc-tion of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods 241:69-81
8. Lyakh LA et al (2002) Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions. Blood 99: 600-608
9. Cao H et al (2000) In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res 9:183-194
10. Lemarie C et al (2007) Purification of mono-cytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device. J Immunol Methods 318:30-36
11. Gulen D et al (2008) Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Int Immunopharmacol 8:1728-1736
12. Zhou Y et al (2003) Commercial scale production of dendritic cells for cancer immunother-apy. Proc Am Assoc Cancer Res 44:2876A
13. Thurner B et al (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1-15
14. Whiteside TL et al (2009) Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 16: 233-240
15. Padley DJ et al (2001) Mature myeloid dendritic cells for clinical use prepared from cd14+ cells isolated by immunomagnetic adsorption. J Hematother Stem Cell Res 10:427-29
16. Wong EC et al (2002) Development ofa closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy 4:65-76
17. Bender J (2000) Next generation clinical systems for the production of dendritic cells. Clin Appl Immunol Rev 1:37-44
18. Suen Y et al (2001) Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 3:365-375
19. Gajdosikova A et al (2006) Acute toxicity of magnetic nanoparticles in mice. Neuro Endocrinol Lett 27(Supplement 2):96-99
20. Berger T et al (2005) Efficient elutriation of monocytes within a closed system (Elutra™) for clinical-scale generation of dendritic cells. J Immunol Methods 298:61-72
21. Stockwin LH et al (2002) Engineered expression of the Coxsackie B and adenovirus receptor (CAR) in human dendritic cells enhances recombinant adenovirus-mediated gene transfer. J Immunol Methods 259:205-215
22. Verhaagh S et al (2006) Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J Gen Virol 87:255-265
23. Lore K et al (2007) Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunc-tional memory T cell responses. J Immunol 179:1721-1729
24. Dietz AB et al (2001) Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression. Gene Ther 8:419-423
25. Adams WC, Loré K (2011) Recombinant ade-novirus vector infection of human dendritic cells. DOI:10.5772/20255
26. Bergelson JM et al (1997) Isolation of a common receptor for coxsackie B viruses and ade-noviruses 2 and 5. Science 275:1320-1323
27. Hemmi S et al (1998) The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 9:2363-2373
28. Tillman BW et al (1999) Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 162:6378-6383
29. Einfeld DA et al (2001) Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 75:11284-11291
30. Papagatsias T et al (2008) Activity of different vaccine-associated promoter elements in human dendritic cells. Immunol Lett 115:117-125